Prevention of Type 1 Diabetes : NIDDK

Prevention of Type 1 Diabetes

This program includes studies on drug development, and cellular therapy that are being proposed to prevent type 1 diabetes.

Areas of particular interest are:

  • Studies on drug development for type 1 diabetes treatment or prevention:
  • Studies including the creation of animal models for therapy trials or humans to maintain normal blood glucose levels.
  • Tolerance induction for prevention of type 1 diabetes
  • Immune intervention
  • "Humanized" mouse model (development of transgenic NOD with human HLA molecules on the T cells) for type 1 diabetes
  • Development of therapies for prevention of Impaired Glucose Tolerance (IGT) or interventions to prevent conversion of IGT to type 1 diabetes
  • Drugs designed to enhance peripheral glucose metabolism or reduce hepatic glucose production of type 1 diabetics
  • Therapies designed to increase insulin sensitivity of type 1 diabetics

For more information, contact Dr. Beena Akolkar, Immunopathogenesis and Genetics of Type 1 Diabetes Program Director.

Resources for Researchers

Clinical Research

Centers

Committees and Advisory Groups

Related Study Sections

NIDDK Staff

Funding Opportunities

Funding for Special Communities

Conferences

Related Reports

Related Organizations

See Also

Page last updated: January 05, 2009

General inquiries may be addressed to: Office of Communications & Public Liaison
NIDDK, NIH
Building 31. Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
USA
For information about NIDDK programs: 301.496.3583

The National Institutes of Health   Department of Health and Human Services   USA.gov is the U.S. government's official web portal to all federal, state, and local government web resources and services.  HONcode Seal - Link to the Health on the Net Foundation